NEW YORK (GenomeWeb) – Novacyt said today that it has completed a €3 million ($3.3 million) private financing.

The clinical diagnostics firm will use net proceeds from the fundraising to invest in a new manufacturing facility in Camberley, UK, to accommodate increased manufacturing of Lab21 clinical laboratory products and the NOVAprep liquid-based cytology platform for cervical cancer screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.